Literature DB >> 11097368

Centriacinar region inflammatory disease in young individuals: a comparative study of Miami and Los Angeles residents.

R P Sherwin1, V Richters, P Kraft, A Richters.   

Abstract

Semiquantitative measurements of chronic inflammation of the centriacinar region (proximal acinus of lung) were compared between 20 Miami and 18 Los Angeles residents (ages 11-30 years) for whom smoking histories were available. Mean extent and severity scores of four lung sites were higher for Los Angeles than Miami residents, with effect of city statistically significant for extent (P=0.02). Also, maximum scores for extent and severity by city were significantly greater for Los Angeles residents (P=0.02, each), but not by smoking history. Smokers did have higher scores for mean extent and severity (by lung site and smoking history), but neither this nor inclusion of smoking and city in the model reached significance. With respect to maximum extent and maximum severity scores, a stratified comparison of cities by smoking history showed a trend (not significant) toward higher scores for Los Angeles residents. Mean extent and severity scores for the lower lobe were higher for basilar sections than for apical sections (each P<0.001). Cumulative data indicate that expanded pathologic studies are essential for efforts to complete a convergence of epidemiological and experimental data implicating exceedences of the Federal ozone standard as a contributor to human lung injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11097368     DOI: 10.1007/s004280000262

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  2 in total

1.  Ozone--42 years later.

Authors:  David V Bates
Journal:  Can Respir J       Date:  2006 Jul-Aug       Impact factor: 2.409

2.  Topographical distribution of bronchial eosinophilia: significance for biopsy diagnosis.

Authors:  Russell P Sherwin; Valda Richters
Journal:  Virchows Arch       Date:  2009-06-03       Impact factor: 4.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.